Shree Krishna Lifecare

Shree Krishna Lifecare, established in 1996 as Shreekrishna Distributers, transitioned to its current name in 2017. The company is headquartered in Mumbai, India, at 606 Ratan Galaxie, Near Mehul Cine Ma, J N Road, Mulund West. It operates as a privately held entity, with ownership details not publicly disclosed. The Corporate Identification Number (CIN) is not available in the provided sources. Specific revenue figures and employee count are not publicly disclosed. The company's official website is sklifecare.com.

Shree Krishna Lifecare specializes in the export and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has established a strong global presence, leveraging over two decades of market expertise to build sustainable relationships with clients. Their product portfolio spans various therapeutic categories, with a notable focus on oncology, antiretrovirals, and cardiometabolic diseases.

Specific details regarding Shree Krishna Lifecare's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company emphasizes sourcing products from reputed manufacturers and authorized agents, ensuring the highest international quality standards.

The founder and visionary behind Shree Krishna Lifecare is Mr. Sandeep Modi, who established the company in 1996. His leadership is characterized by a strong work ethic and a commitment to transparency, fostering long-term relationships with clients. Specific details about other key executives, such as the CEO, CFO, and their respective roles, are not publicly available.

Shree Krishna Lifecare's export data indicates a focus on the advanced oncology therapeutic category, with products like Pembrolizumab and Ibrutinib. However, specific regulatory filings, approvals, and market access statuses in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers suggests adherence to international regulatory standards, but detailed information is not available.

Shree Krishna Lifecare's export data does not specify shipments to Africa, Latin America, or Southeast Asia. The company's focus on oncology, antiretrovirals, and cardiometabolic diseases aligns with global health priorities, potentially facilitating access to emerging markets. However, specific information regarding WHO prequalification or market penetration in these regions is not publicly available.

Shree Krishna Lifecare's export data reveals a concentrated portfolio, with the top five products accounting for 100% of the export value. This indicates a high level of concentration risk. The company's strategic direction appears to focus on oncology, as evidenced by the prominence of products like Pembrolizumab and Ibrutinib. Diversification into other therapeutic areas or markets could mitigate potential risks associated with this concentration.

Specific details regarding Shree Krishna Lifecare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers suggests compliance with international regulatory standards, but detailed information is not available.

Shree Krishna Lifecare's export data indicates a focus on oncology products, which are subject to stringent regulatory standards. However, specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines (EDQM) status is not publicly available. The company's commitment to quality suggests adherence to international standards, but detailed certifications are not disclosed.

Specific details regarding Shree Krishna Lifecare's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers and authorized agents suggests compliance with Indian regulatory standards, but detailed information is not available.

There is no publicly available information regarding Form 483 observations, warning letters, or import alerts associated with Shree Krishna Lifecare. The company's focus on sourcing from reputed manufacturers and authorized agents suggests a commitment to maintaining high-quality standards and regulatory compliance.

Shree Krishna Lifecare operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified in the provided data, the company's emphasis on sourcing from reputed manufacturers and authorized agents positions it to compete effectively in the global market. The concentration of its portfolio on a few products may limit its competitive edge compared to more diversified competitors.

Shree Krishna Lifecare's key differentiators include its two-decade-long market expertise, commitment to sourcing genuine products from reputed manufacturers, and a strong global presence. The company's focus on oncology, antiretrovirals, and cardiometabolic diseases aligns with global health priorities, potentially enhancing its appeal in these therapeutic areas.

Shree Krishna Lifecare's current strategic direction appears to focus on exporting finished pharmaceutical formulations in the oncology therapeutic category. The company's emphasis on sourcing from reputed manufacturers and authorized agents suggests a commitment to quality and regulatory compliance. Future strategic directions may include diversification into other therapeutic areas or markets to mitigate concentration risks and enhance growth opportunities.

Shree Krishna Lifecare's export data indicates a reliance on a limited number of products, with the top five accounting for 100% of the export value. This suggests a concentrated supplier base. The company's emphasis on sourcing from reputed manufacturers and authorized agents indicates a focus on quality and reliability. However, the lack of publicly available information regarding specific suppliers and their performance metrics limits a comprehensive assessment.

Importers should verify the following certifications when considering products from Shree Krishna Lifecare:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the manufacturer directly.

• WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice (GMP) standards. This can be verified by checking the WHO's official list of prequalified manufacturers.

• EU GMP Certification: Verify that the products meet the European Union's GMP standards. This information is typically available through the European Medicines Agency (EMA) or the European Directorate for the Quality of Medicines (EDQM).

• ISO Certification: Check for ISO certifications related to quality management systems, such as ISO 9001. These certifications can be verified through the International Organization for Standardization's official website.

When conducting due diligence on Shree Krishna Lifecare, consider the following steps:

• Verify Regulatory Approvals: Confirm that the products have the necessary approvals from relevant regulatory bodies, such as the FDA, WHO, and EU authorities.

• Assess Manufacturing Standards: Ensure that the manufacturing facilities adhere to recognized quality standards, such as WHO-GMP and EU GMP.

• Evaluate Product Quality: Review product quality reports, certificates of analysis, and any available third-party testing results.

• Check Financial Stability: Assess the company's financial health by reviewing available financial statements or reports.

• Review Supply Chain Practices: Understand the company's supply chain practices, including sourcing, storage, and distribution methods.

• Monitor for Red Flags: Be alert to any signs of regulatory non-compliance, quality issues, or financial instability.

By following this checklist, importers can make informed decisions and mitigate potential risks associated with sourcing from Shree Krishna Lifecare.